Viagra vs Vardenafil (Levitra/Staxyn): Real-World Evidence Comparison

What Do the Key Trials Actually Show About Efficacy?

Sildenafil and vardenafil both demonstrate statistically significant improvements over placebo in erectile function domain (EFD) scores, but the absolute numbers differ in ways that matter clinically. Head-to-head data, not just placebo-controlled trials, are the right lens here.

The Sildenafil Landmark Data

The first large randomized controlled trial of sildenafil, Goldstein et al. (NEJM, 1998, N=861), reported that 69% of all attempts at sexual intercourse were successful in the sildenafil group vs 22% in the placebo group across doses from 25 to 100 mg. 1 International Index of Erectile Function (IIEF) scores improved by a mean of 7.7 points on sildenafil vs 1.7 points on placebo. That 1998 dataset remains one of the most-cited efficacy benchmarks in men's sexual health.

Generic sildenafil entered the U.S. Market in December 2017 after Pfizer's primary patent expired, and the FDA maintains a current list of approved generic sildenafil citrate products. 2

The Vardenafil Landmark Data

Porst et al. (Int J Impot Res, 2003, N=805) evaluated vardenafil 5, 10, and 20 mg in men with mild-to-severe ED. The 20 mg dose produced a mean IIEF-EFD score improvement of 8.0 points over baseline vs 1.7 points for placebo (P<0.001). Successful intercourse attempts reached 75% with vardenafil 20 mg vs 52% with placebo. 3 That 23-percentage-point gap over placebo is numerically similar to sildenafil's performance in the Goldstein trial, though cross-trial comparisons carry obvious limitations.

Direct Head-to-Head Evidence

A Cochrane systematic review of PDE5 inhibitors found no statistically significant difference in IIEF score improvement between sildenafil and vardenafil when trials were pooled and adjusted for dose equivalence. 4 The review covered 82 trials and over 32,000 men, making it the most comprehensive comparative dataset available.

Pharmacokinetics: Onset, Duration, and the Fat-Meal Problem

Understanding why the two drugs feel different to patients starts with pharmacokinetics, not efficacy statistics alone.

Onset and Tmax

Sildenafil reaches peak plasma concentration (Tmax) at approximately 60 minutes under fasting conditions, per FDA-approved prescribing information. 5 Vardenafil's Tmax is approximately 30 to 45 minutes under similar conditions, a 15-to-30-minute advantage that patients notice in real-world use. Faster onset is consistently the top self-reported reason men prefer vardenafil in patient-reported outcome studies.

The High-Fat Meal Effect

A high-fat meal (roughly 57% fat content) delays sildenafil's Tmax by approximately 60 minutes and reduces Cmax by 29%, according to the drug's original pharmacokinetic studies referenced in its prescribing label. 5 Vardenafil is much less sensitive: a high-fat meal reduces Cmax by only about 18 to 20% with no significant Tmax shift, as noted in the Levitra prescribing information. 6 For men who eat dinner before sexual activity, this difference can be meaningful.

Duration

Both drugs provide a therapeutic window of roughly 4 to 6 hours, though individual metabolism varies considerably based on CYP3A4 activity. Tadalafil (Cialis) is the alternative when a 24-to-36-hour window is needed, a different clinical question than the sildenafil-vs-vardenafil comparison.

Staxyn: The Orally Disintegrating Vardenafil Formulation

Staxyn is a 10 mg orally disintegrating tablet (ODT) of vardenafil, approved by the FDA in 2010. 7 It dissolves on the tongue without water, which some men find more discreet than swallowing a tablet.

Bioavailability Differences Between Staxyn and Levitra

The Staxyn ODT formulation is not bioequivalent to the Levitra film-coated tablet at the same 10 mg dose. The ODT produces approximately 21% higher Cmax compared to the conventional tablet, per the Staxyn prescribing label. 7 Clinicians switching patients from Levitra 10 mg to Staxyn 10 mg should note this difference: the higher peak exposure may increase side-effect frequency in sensitive individuals.

Who Benefits from the ODT Format

Men who have difficulty swallowing tablets, those seeking discretion in social settings, and patients with certain neurological conditions affecting swallowing are the clearest candidates. Staxyn is not substitutable for Levitra at a 1:1 ratio on pharmacy dispensing systems, generic vardenafil tablets are bioequivalent to Levitra, not to Staxyn.

Side-Effect Profiles: Where the Two Drugs Diverge

Both agents share the PDE5 inhibitor class side-effect profile. The divergence is in two specific areas: visual disturbance and nasal symptoms.

Shared Side Effects

Headache (sildenafil 16%, vardenafil 15%), flushing (sildenafil 10%, vardenafil 11%), and rhinitis occur at nearly identical rates in placebo-controlled trial data. 3 1 Dyspepsia is more common with sildenafil (7% vs 4% for vardenafil), a detail that matters for men with reflux or gastric sensitivity.

Visual Side Effects

Sildenafil has mild cross-reactivity with PDE6, an enzyme in retinal photoreceptors. This produces the well-known transient blue-tinge or altered light-perception effect (cyanopsia) that occurs in approximately 3% of sildenafil users at 50 to 100 mg. 1 Vardenafil has a higher PDE5 selectivity ratio over PDE6 than sildenafil, which is why color-vision disturbance is rarely reported with vardenafil at standard doses.

QTc Prolongation Warning

Vardenafil carries a label warning about QTc prolongation. Men taking Class IA antiarrhythmics (quinidine, procainamide) or Class III antiarrhythmics (amiodarone, sotalol) should not use vardenafil. 6 This QTc signal is absent from sildenafil's label at standard doses, making sildenafil the preferred PDE5 inhibitor in men on those cardiac medications.

Drug Interactions and Contraindications

Both sildenafil and vardenafil are absolutely contraindicated with all nitrate medications. The FDA has warned that combining any PDE5 inhibitor with organic nitrates can produce severe, potentially fatal hypotension. 8 This applies to nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and amyl nitrite (poppers).

Alpha-Blocker Interactions

Both drugs cause additive blood-pressure reduction when combined with alpha-blockers (tamsulosin, terazosin, doxazosin). The Levitra label requires a minimum 6-hour separation between an alpha-blocker and vardenafil. 6 For men with BPH who take alpha-blockers daily, the alpha-blocker interaction must be factored into timing.

CYP3A4 Inhibitors

Both drugs are metabolized primarily by CYP3A4. Strong inhibitors, ritonavir, ketoconazole, itraconazole, increase plasma levels of both sildenafil and vardenafil substantially. Ritonavir increases sildenafil AUC by approximately 11-fold; a maximum sildenafil dose of 25 mg per 48 hours is recommended in that setting. 5 Vardenafil dose must be reduced to 2.5 mg per 24 hours with ketoconazole 400 mg. 6

Real-World Evidence: Patient Satisfaction and Switching Patterns

Randomized trial data establish that both drugs work. Real-world evidence answers the more practical question: which drug do men actually prefer, and why do they switch?

Preference Studies

A multicenter crossover preference study published in the European Urology literature (Porst et al.) found that when men with ED tried both sildenafil and vardenafil in randomized order, approximately 55% preferred vardenafil and 45% preferred sildenafil, a difference that was not statistically significant at the group level, though individual preferences were strong. 3 The drivers of individual preference were onset speed and reduced food-timing concern, not differences in ultimate erection quality.

Why Men Switch From Sildenafil to Vardenafil

The most common switch triggers reported in clinical practice and post-marketing surveys include:

• Food timing frustration (eating before sexual activity and losing efficacy)
• Visual side effects (blue tinge, sensitivity to light)
• Desire for faster onset
• Dyspepsia or facial flushing that does not improve at lower doses

A 2020 analysis of PDE5 inhibitor prescribing patterns using U.S. Claims data found that approximately 18% of men who initiated sildenafil switched to another PDE5 inhibitor within 12 months, with vardenafil and tadalafil capturing roughly equal shares of those switches. 9

Why Men Switch From Vardenafil to Sildenafil

Cost drives most reverse switches. Generic sildenafil 100 mg tablets can be split and purchased for under $1 per dose in many U.S. Pharmacies, while generic vardenafil remains somewhat more expensive per pill. Generic availability for both arrived within a year of each other, sildenafil in December 2017, vardenafil in 2018, but the sildenafil supply chain matured faster, producing deeper price competition.

Special Populations: Diabetes, Post-Prostatectomy, and Cardiovascular Disease

ED is not a uniform condition. The underlying cause shapes which PDE5 inhibitor performs better.

Diabetic ED

Men with diabetes-associated ED often have more severe baseline impairment due to combined neuropathic and vascular damage. The Goldstein trial included a diabetic subgroup in which sildenafil 50 to 100 mg produced a 57% successful intercourse rate vs 10% for placebo. 1 A separate analysis of vardenafil in 452 men with type 1 or type 2 diabetes showed a mean IIEF-EFD improvement of 6.4 points vs 1.9 points for placebo. 3 Both drugs work in diabetic men; neither shows clear superiority in this population.

Post-Radical Prostatectomy

Post-prostatectomy ED responds more slowly to PDE5 inhibitors due to cavernous nerve injury. Response rates are lower for both sildenafil and vardenafil compared to organic or psychogenic ED, and nightly low-dose rehabilitation protocols have been studied for sildenafil (25 mg nightly) without clear superiority of either agent in this indication. 10

Cardiovascular Disease

The Princeton III Consensus guidelines provide the framework for PDE5 inhibitor use in men with cardiovascular disease. Men categorized as low cardiovascular risk (stable angina managed without nitrates, controlled hypertension, mild valvular disease) can use either PDE5 inhibitor without cardiology clearance. 11 The absolute contraindication to nitrates applies equally to both drugs.

Dosing Protocols and Practical Administration

The following clinical decision framework reflects HealthRX prescribing practice for men choosing between sildenafil and vardenafil. It synthesizes FDA label guidance and the comparative trial data above.

Step 1, Establish baseline. Use the IIEF-5 (abridged IIEF) to score severity: mild (17 to 21), mild-moderate (12 to 16), moderate (8 to 11), severe (5 to 7).

Step 2, Select starting drug based on lifestyle factors.

• Predictable sexual activity timing, no food concerns, price-sensitive: start sildenafil 50 mg.
• Spontaneous activity, high-fat diet, faster onset wanted, or visual side effects on sildenafil: start vardenafil 10 mg.
• Difficulty swallowing, discretion needed: start Staxyn 10 mg ODT (note higher Cmax).
• Antiarrhythmic medications (Class IA or III): sildenafil only; vardenafil contraindicated.

Step 3, Titrate after four attempts. If the IIEF-5 score has not improved by at least 4 points after four separate attempts, titrate up one dose level (sildenafil 50 to 100 mg; vardenafil 10 to 20 mg) before switching drug class.

Step 4, Switch drug after two failed dose levels. Two failed doses on one agent is the threshold to cross to the other PDE5 inhibitor or to consider tadalafil 5 mg daily for continuous coverage.

Patients should take either drug on an empty stomach or after a low-fat meal for best results. Administration more than once per 24-hour period is not recommended for either agent. 5 6

Cost and Access in 2025

Generic sildenafil 20 mg tablets (originally approved for pulmonary arterial hypertension as Revatio) can be prescribed off-label for ED at a dose of five 20 mg tablets (100 mg total), often at a cost below $15 for a 30-tablet supply at discount pharmacies. Generic sildenafil 25, 50, and 100 mg branded-equivalent tablets are also widely available at $1 to 3 per dose with GoodRx-type coupons.

Generic vardenafil 5, 10, and 20 mg tablets became available in 2018 and typically cost $3 to 8 per dose through discount programs. The Staxyn ODT remains branded in most markets and may cost $25 to 40 per tablet without insurance coverage, making it the most expensive option in this comparison.

The American Urological Association guidelines note that cost is a legitimate clinical consideration in PDE5 inhibitor selection, since all approved agents have comparable efficacy at therapeutic doses. 12